Wang Lihua, Liu Guangyang, Zheng Libo, Long Haomiao, Liu Yongjun
Stem Cell Biology and Regenerative Medicine Institution, Yi-Chuang Institute of Bio-Industry, Beijing, China.
Ann Transl Med. 2023 Jun 30;11(9):321. doi: 10.21037/atm-22-3882. Epub 2023 May 9.
With the development of cytology and genomics, genetically modified immune cells have established their role from principle to clinical applications, achieving outstanding therapeutic effects in hematologic malignancies. However, even though encouraging initial response rates, many patients experience a relapse. In addition, there are still many obstacles preventing the use of genetically modified immune cells in treating solid tumors. Nevertheless, the therapeutic effect of genetically engineered mesenchymal stem cells (EMSCs) in malignant diseases, especially solid tumors, has been widely investigated, and related clinical trials are gradually being carried out. This review aims to describe the progress of gene and cell therapy and the current status of stem cell clinical trials in China. This review focuses on the research and application prospects of genetically engineered cell therapy using chimeric antigen receptor (CAR) T cells and mesenchymal stem cells (MSCs) for cancer.
A literature search of PubMed, SpringerLink, Wiley, Web of Science, and Wanfang database was carried out for published articles on gene and cell therapy up to August 2022.
This article reviews the development of gene and cell therapy and the current status of the development of stem cell drugs in China, with a particular focus given to the advent of the novel therapy of EMSCs.
Gene and cell therapies have a promising therapeutic effect on many diseases, especially recurrent and refractory cancers. Further development of gene and cell therapy is expected to promote precision medicine and individualized therapy and open a new era of therapy for human diseases.
随着细胞学和基因组学的发展，基因改造免疫细胞已从理论走向临床应用，并在血液系统恶性肿瘤中取得了显著的治疗效果。然而，尽管初始缓解率令人鼓舞，但许多患者仍会复发。此外，在使用基因改造免疫细胞治疗实体瘤方面仍存在诸多障碍。尽管如此，基因工程化间充质干细胞（EMSCs）在恶性疾病尤其是实体瘤中的治疗作用已得到广泛研究，相关临床试验也在逐步开展。本综述旨在描述中国基因与细胞治疗的进展以及干细胞临床试验的现状。本综述重点关注嵌合抗原受体（CAR）T细胞和间充质干细胞（MSCs）用于癌症的基因工程细胞治疗的研究及应用前景。
在PubMed、SpringerLink、Wiley、Web of Science和万方数据库中检索截至2022年8月发表的关于基因与细胞治疗的文章。
本文综述了基因与细胞治疗的发展以及中国干细胞药物的开发现状，特别关注了EMSCs这一新型疗法的出现。
基因与细胞治疗对许多疾病，尤其是复发难治性癌症具有良好的治疗效果。基因与细胞治疗的进一步发展有望推动精准医学和个体化治疗，开启人类疾病治疗的新时代。
